SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (267)9/24/2002 6:47:28 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 1840
 
Good, gutsy call:

Message 17958820

Btw, what is your prediction for Iressa?
My is positive recommendation by AC.

thestreet.com

In a dramatic, and somewhat stunning comeback, an advisory panel of the Food and Drug Administration voted Tuesday to recommend approval for the drugmaker's experimental cancer drug, Iressa ...

Stunning to Adam, I guess, and yes this is not over by any stretch.

PB



To: Miljenko Zuanic who wrote (267)9/24/2002 6:51:10 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 1840
 
>> AC panel was not able to close ayes from ~10% response rate <<

Great call. Never deviated from your strong line. Congrats!

As for head and neck and IMCL, I've, until recently, always sided with the oncologists who have said (paraphrased) "look, I know a dramatic response when I see one, and some patient responses are dramatic". But, I must admit, I lost faith. IMCL disease, the fear of running with rats.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News